Molecular Partners AG (NAS:MOLN)
$ 5.3 -0.01 (-0.19%) Market Cap: 195.73 Mil Enterprise Value: 38.95 Mil PE Ratio: 0 PB Ratio: 1.10 GF Score: 62/100

Molecular Partners AG at Cowen Healthcare Conference (Virtual) Transcript

Mar 02, 2021 / 03:30PM GMT
Kenneth Charles Cacciatore
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Great. Well, thanks to Patrick, Andreas and Seth for joining both Stacy and Georgi and I on this conversation.

These are -- obviously, we go back a long way, all the way to the IPO. And there's been evolution in the story, but the consistency here is clearly constant innovation. And you all, to your credit, have I think pushed this company tremendously far down the path here. And you've done it with a lot of efficiency, so to -- credit to you all.

Questions & Answers

Kenneth Charles Cacciatore
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

And I think that's something maybe we should highlight in the Q&A, as to where you've gotten into the level of lack of burn, I would say, to get to where you were, but maybe, Patrick, for folks that are joining that are newer to the story, just briefly, before we get into the -- to more of the details, why don't we talk a little bit about an overview of your DARPin

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot